1. Academic Validation
  2. Cobicistat, a pharmacoenhancer for HIV treatments

Cobicistat, a pharmacoenhancer for HIV treatments

  • Drugs Today (Barc). 2013 Apr;49(4):233-7. doi: 10.1358/dot.2013.49.4.1947288.
Z Temesgen 1
Affiliations

Affiliation

  • 1 Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA. temesgen.zelalem@mayo.edu
Abstract

Cobicistat is a novel Cytochrome P450 3A4 (CYP3A4) inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs. It lacks significant anti-HIV activity and is more selective than ritonavir in its Enzyme inhibition. In addition, its water solubility may lend itself to coformulation with other drugs. Renal adverse effects and a considerable drug interaction potential limit its clinical utility and caution is required when using it. A fixed-dose combination product containing cobicistat in addition to elvitegravir, tenofovir and emtricitabine, and providing a one-pill, once-a-day, antiretroviral regimen was recently approved.

Keywords

Cobicistat; Cytochrome P450 3A4 inhibitors; GS-9350; Pharmacoenhancer.

Figures
Products